Disease/Infection News

RSS

Pathogenic listeria tricks intestinal cells to cause sickness

Pathogenic listeria tricks intestinal cells into helping it pass through those cells to make people ill, and, if that doesn't work, the bacteria simply goes around the cells, according to a Purdue University study.

26 Oct 2010

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced positive results from a Phase I/II challenge study of its norovirus virus-like particle (VLP) vaccine candidate.

26 Oct 2010

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today the results of a clinical trial of its investigational Fluzone Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

26 Oct 2010

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.

26 Oct 2010

Researchers investigate impact of fungal toxin on birth defects

A Creighton University School of Medicine researcher has been awarded a $2.7 million grant by the National Institutes of Health (NIH) to investigate a possible link between the ingestion of tortillas and corn-based food products contaminated with a fungal toxin and increased risk for birth defects.

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

Northern Territory reports worst mosquito plague ever

Authorities in Australia’s Northern Territory report the worst mosquito plague since records began in 1979. An organization helping homeless people in Darwin is distributing insect repellent and coils to combat the mosquito onslaught.

25 Oct 2010

Haiti cholera epidemic abates

The rate of deaths in Haiti's cholera epidemic slowed on Monday. This followed a multinational medical operation scale up to limit the spread of an outbreak that has killed 259 people in the earthquake-hit country. However Haitian and international health authorities are still bracing for more cases before the epidemic is finally controlled. So far, the epidemic has mostly impacted two rural central Haitian provinces, Artibonite and Center, along with the few isolated cases in the capital Port-au-Prince. Suspected cases have also been reported in the Nord and Sud provinces.

25 Oct 2010

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

Inviragen, a company developing vaccines to protect against infectious diseases worldwide, and the Program for the Study and Control of Tropical Diseases (PECET), jointly announced the initiation of a Phase 1 clinical trial of DENVax™ in Colombia. DENVax is an investigational vaccine designed to provide protection against all four dengue virus serotypes. The trial will measure the safety of DENVax as well as the immune responses induced by the vaccine in healthy adults in Rionegro, Colombia.

25 Oct 2010

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.

25 Oct 2010

World Vision increases response in cholera affected Haiti

As the cholera outbreak continues to spread in the Artibonite region of Haiti, World Vision is increasing its response in affected areas, pre-positioning much-needed health supplies and preparing residents in its displacement camps in Port-au-Prince with critical, life-saving health and hygiene messages.

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

Non communicable diseases will cost India USD237 billion during 2006-15

Health experts participating at a roundtable organised by India Health Progress(IHP) on economic and social impact of non-communicable diseases in India are of the opinion that a concerted effort is required to address the growing burden.

25 Oct 2010

Popular Mechanics recognizes three NSF-funded projects with innovation Breakthrough Awards

Popular Mechanics has recognized three NSF-funded projects with innovation Breakthrough Awards: an artificial retina returning sight to those who have lost it; a system that uses "controlled rocking" and energy-dissipating fuses to help buildings withstand earthquakes; and an inexpensive medical microscope built for cell-phones that allows doctors in rural villages to identify malaria-infected blood cells.

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

New synthetic population can help computational modelers to study infectious diseases

To help computational modelers who study the spread of infectious diseases, including flu, researchers supported by the National Institutes of Health at RTI International in North Carolina created a synthetic population mirroring U.S. demographics. Now they've added another layer of realism: where the virtual citizens live.

25 Oct 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

25 Oct 2010

New disease map resource can reduce MRSA infection in hospitalized patients

Gary A. Puckrein, Ph.D., CEO of the National Minority Quality Forum, and Gary Doern, Ph.D., nationally recognized infectious disease expert, will host the launch of the national MRSA Atlas by way of a webinar.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

Incidence of KPC-producing bacteria is rising in Chicago

In a survey of Chicago-area healthcare facilities, researchers at Rush University Medical Center and the Cook County Department of Public Health have found that the incidence of KPC-producing bacteria is rising. These bugs cause infections with high mortality rates and are resistant to the most commonly used antibiotics.

25 Oct 2010

Disease/Infection News

Pathogenic listeria tricks intestinal cells to cause sickness

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Researchers investigate impact of fungal toxin on birth defects

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Northern Territory reports worst mosquito plague ever

Haiti cholera epidemic abates

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

World Vision increases response in cholera affected Haiti

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Non communicable diseases will cost India USD237 billion during 2006-15

Popular Mechanics recognizes three NSF-funded projects with innovation Breakthrough Awards

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

New synthetic population can help computational modelers to study infectious diseases

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

New disease map resource can reduce MRSA infection in hospitalized patients

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Incidence of KPC-producing bacteria is rising in Chicago

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News